Sigma Of Australia Inks Due-Diligence Pact With Suitor Aspen
This article was originally published in PharmAsia News
Australia's Sigma Pharmaceuticals moved closer to its acquisition by South Africa's Aspen Pharmacare as the two firms agreed on due-diligence procedures that could lead to closing the $591 million deal
You may also be interested in...
After its historic first emergency approval, analysts at Bernstein has upgraded predictions for Pfizer's COVID-19 vaccine in 2021 and beyond.
How UK and EU device regulations will differ in 2021, UK approved bodies and Northern Ireland's unfettered access to the UK market were key themes at the ABHI’s annual regulatory conference.
Regulatory pressure to fully approve the first COVID-19 vaccine in China is mounting as top officials tour an inspection agency and two leading manufacturers.